Iovance: Buy Now Before Many Growth Catalysts Kick In (NASDAQ:IOVA)
· seekingalpha.com
Iovance raised 2026 revenue guidance as Amtagvi adoption accelerates with broader access, physician awareness, and faster manufacturing. Learn more about IOVA stock here.
I am initiating coverage on Iovance Biotherapeutics, Inc. ( IOVA ) with a bullish view. The stock is up more than 5x this year so far, but I think there is ampl...